Integra LifeSciences (NASDAQ:IART) Sets New 52-Week High – Time to Buy?

Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $19.07 and last traded at $18.9650, with a volume of 54640 shares changing hands. The stock had previously closed at $18.40.

Analyst Upgrades and Downgrades

IART has been the topic of a number of research reports. BMO Capital Markets started coverage on Integra LifeSciences in a research note on Wednesday, July 8th. They set a “market perform” rating and a $19.00 price target on the stock. Weiss Ratings raised Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, May 13th. Wall Street Zen raised Integra LifeSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Truist Financial lowered their target price on Integra LifeSciences from $13.00 to $12.00 and set a “hold” rating for the company in a report on Wednesday, April 15th. Finally, Wells Fargo & Company lifted their target price on Integra LifeSciences from $12.00 to $15.00 and gave the company an “equal weight” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $17.17.

Integra LifeSciences Price Performance

The company’s 50-day simple moving average is $16.59 and its 200 day simple moving average is $12.94. The company has a market cap of $1.46 billion, a PE ratio of -2.92, a PEG ratio of 1.29 and a beta of 1.22. The company has a debt-to-equity ratio of 1.75, a quick ratio of 1.95 and a current ratio of 3.38.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.13. The business had revenue of $391.92 million for the quarter, compared to analyst estimates of $381.81 million. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The company’s revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.41 earnings per share. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. On average, sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Global Retirement Partners LLC purchased a new stake in shares of Integra LifeSciences during the fourth quarter worth approximately $25,000. Osaic Holdings Inc. lifted its stake in Integra LifeSciences by 36.6% in the second quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares during the last quarter. GAMMA Investing LLC grew its holdings in Integra LifeSciences by 145.9% during the 4th quarter. GAMMA Investing LLC now owns 6,307 shares of the life sciences company’s stock worth $78,000 after acquiring an additional 3,742 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Integra LifeSciences by 595.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,958 shares of the life sciences company’s stock valued at $98,000 after purchasing an additional 6,814 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in shares of Integra LifeSciences in the 4th quarter valued at $124,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.